A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas(†)

The objective of this phase I study was to determine the maximal tolerated dose (MTD) of erlotinib in patients with recurrent malignant gliomas (MGs) or recurrent meningiomas on enzyme-inducing antiepileptic drugs (EIAEDs). Dose escalation was by a standard 3 × 3 design. The initial starting dose of...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Raizer, Jeffrey J., Abrey, Lauren E., Lassman, Andrew B., Chang, Susan M., Lamborn, Kathleen R., Kuhn, John G., Yung, W.K. Alfred, Gilbert, Mark R., Aldape, Kenneth D., Wen, Patrick Y., Fine, Howard A., Mehta, Minesh, DeAngelis, Lisa M., Lieberman, Frank, Cloughesy, Timothy F., Robins, H. Ian, Dancey, Janet, Prados, Michael D.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Oxford University Press 2010
Soggetti:
Clinical Investigations
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC2940559/
https://ncbi.nlm.nih.gov/pubmed/20150371
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nop017
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi